The outcomes revealed no statistically significant distinctions in the distribution of PLK1 expression and p-PLK1 among NKTCL patients concerning gender, age, Ann Arbor stage, PINK-E score, B-symptoms, lactate dehydrogenase, β2-microglobulin, blood EBV-DNA, bone marrow invasion, and lymph node metastasis (p > 0.05). This evidence concerns the gene PLK1 and metastatic malignant neoplasm in the lymph nodes.